CAREERS We are pushing further, discovering more, and redefining treatment expectations for patients and providers. But as passionate as we are about our work, we’re equally passionate about doing everything with integrity, ethics, and inclusion. Careers We live, breathe, and sleep scientific innovation. It’s the “why” behind everything we do. If you are driven by […]
OUR SCIENCE THE TARGET GSK-3β has long been an attractive target in cancer therapy, but previous drug candidates developed to inhibit GSK-3β have been limited by poor pharmaceutical characteristics and/or significant adverse effects in patients, limiting their clinical utility. The Function of GSK-3β GSK-3β is an enzyme that regulates a number of intersecting biological pathways
PRIVACY NOTICE Last updated and effective as of December 20, 2023. This Privacy Notice explains the practices that Actuate Therapeutics, Inc. (“Actuate”, “we”, “us”, “our”) follows in connection with the personal data that we collect through this website, when you contact us directly and through our research. We may change this Privacy Notice at any
Elraglusib combination Phase 2 trial with retifanlimab based on observed synergy with immune checkpoint inhibitors, and preclinical and early clinical data supporting immunomodulatory activity of GSK-3β inhibitors CHICAGO, IL and FORT WORTH, TX – March 1, 2022 – Actuate Therapeutics and The University of Kansas Cancer Center today announced the enrollment of the first patient
Elraglusib will be combined with FOLFIRINOX alone or with Losartan in multi-centerPhase 2 clinical study initiated at Massachusetts General Hospital, Fred Hutchinson CancerResearch Center, University of Colorado, Denver, and Johns Hopkins University with studyfunding provided by the Lustgarten Foundation for Pancreatic Cancer Research CHICAGO, IL and FORT WORTH, TX – February 7, 2022 – Actuate
Elraglusib Results in 57% Disease Control Rate and 39% Objective Response Rate inCombination with Gemcitabine/Abraxane in First Line Treatment of Pancreatic Cancer CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, today announced that their Phase 2 open-label single arm study of elraglusib (9-ING-41) plus gemcitabine/nab-paclitaxel treatment met
CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation for 9-ING-41 for treatment of patients with pancreatic cancer. 9-ING-41 is Actuate’s proprietary small molecule glycogen synthase kinase-3 beta (GSK-3β) inhibitor which is being
CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, today announced enrollment of the first patients with first-line advanced pancreatic cancer in a phase 2 study of 9-ING-41, as a new arm of the ongoing phase 1/2 1801 trial of 9-ING-41, (NCT03678883, EudraCT#:2018-003739-32). 9-ING-41 is Actuate’s proprietary small
ACTUATE THERAPEUTICS ANNOUNCES INITIATION OF PHASE 2 CLINICAL STUDY IN PANCREATIC CANCER Read More »
CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, announced today that interim results from their 1801 Phase 1/2 study (NCT03678883, EudraCT #: 2018-003739-32) will be presented at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting which will take place virtually on May 29th, 2020. Dr.
ACTUATE THERAPEUTICS ANNOUNCES 9-ING-41 DATA PRESENTATION AT ASCO ANNUAL MEETING 2020 Read More »
CHICAGO, IL and FORT WORTH, TX – Actuate Therapeutics, Inc. (Actuate), a clinical stage biopharmaceutical company, today announced the initiation of two additional clinical studies with its lead molecule, 9-ING-41, a Glycogen Synthase Kinase beta (GSK-3β) inhibitor. On April 8, the company opened its 1902 study: A Phase 1 study of 9-ING-41, a Glycogen Synthase
ACTUATE THERAPEUTICS ANNOUNCES INITIATION OF ADDITIONAL CLINICAL STUDIES FOR 9-ING-41 Read More »
